| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 92,710 | 80,871 | ||
| Marketable securities | 860,150 | 858,066 | ||
| Accounts receivable, net | 5,029 | 4,986 | ||
| Inventory | 32,034 | 30,848 | ||
| Prepaid expenses and other current assets | 43,186 | 44,693 | ||
| Total current assets | 1,033,109 | 1,019,464 | ||
| Marketable securities | 304,341 | 400,467 | ||
| Operating lease assets | 33,650 | 36,785 | ||
| Property and equipment, net | 10,675 | 10,579 | ||
| Other non-current assets | 3,930 | 3,942 | ||
| Total assets | 1,385,705 | 1,471,237 | ||
| Accounts payable | 19,553 | 17,532 | ||
| Accrued expenses | 37,217 | 35,289 | ||
| Income taxes payable | 0 | 0 | ||
| Operating lease liabilities | 17,987 | 17,589 | ||
| Total current liabilities | 74,757 | 70,410 | ||
| Operating lease liabilities, net of current portion | 26,528 | 31,171 | ||
| Other non-current liabilities | 90 | 101 | ||
| Total liabilities | 101,375 | 101,682 | ||
| Common stock, 0.001 par value 125,000,000 shares authorized 74,496,287 shares issued and 58,279,876 shares outstanding at september30, 2025, and 73,372,696 shares issued and 57,156,285 shares outstanding at december31, 2024 | 74 | 74 | ||
| Additional paid-in capital | 2,538,357 | 2,521,545 | ||
| Accumulated other comprehensive income (loss) | 2,051 | 655 | ||
| Treasury stock, at cost (16,216,411 shares at september30, 2025 and december31, 2024) | 802,486 | 802,486 | ||
| Accumulated deficit | -453,666 | -350,233 | ||
| Total stockholders equity | 1,284,330 | 1,369,555 | ||
| Total liabilities and stockholders equity | 1,385,705 | 1,471,237 | ||
AGIOS PHARMACEUTICALS, INC. (AGIO)
AGIOS PHARMACEUTICALS, INC. (AGIO)